Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?
Crohn’s disease
Inflammatory bowel disease
antibodies to infliximab
immunogenicity
infliximab
infliximab trough levels
subcutaneous
treatment persistence
Journal
Crohn's & colitis 360
ISSN: 2631-827X
Titre abrégé: Crohns Colitis 360
Pays: England
ID NLM: 101752188
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab. Patients with refractory Crohn's disease (CD, Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 μg/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 ( Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.
Sections du résumé
Background
UNASSIGNED
A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab.
Methods
UNASSIGNED
Patients with refractory Crohn's disease (CD,
Results
UNASSIGNED
Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 μg/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 (
Conclusions
UNASSIGNED
Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.
Identifiants
pubmed: 38028954
doi: 10.1093/crocol/otad040
pii: otad040
pmc: PMC10640858
doi:
Types de publication
Journal Article
Langues
eng
Pagination
otad040Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
Déclaration de conflit d'intérêts
K.C.: has consulted for Celltrion and Biogen. D.D.: has consulted for Takeda, AbbVie, Pfizer, and Janssen. M.L.: has consulted for Takeda and Pfizer. M.K.: has consulted for Pfizer. N.M.: has consulted for Takeda and Janssen. V.H.: has consulted for Biogen and Janssen. K.M.: has consulted for Takeda and Janssen. K.K.: has consulted for Abbott. M.K.: has consulted for Takeda and Janssen. J.J.: none. K.K.: none. G.V.: none. S.P.: none. M.L.: provided consultations and received fees for lectures by Celltrion, Abbvie, Janssen, Takeda, and Ferring.
Références
Gastroenterol Hepatol (N Y). 2019 Dec;15(12):656-665
pubmed: 31892912
Biomedicines. 2022 Aug 30;10(9):
pubmed: 36140230
Autoimmun Rev. 2014 Jan;13(1):24-30
pubmed: 23792214
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Autoimmun Rev. 2021 Jul;20(7):102849
pubmed: 33974946
J Crohns Colitis. 2012 Mar;6(2):143-53
pubmed: 22325168
Clin Gastroenterol Hepatol. 2023 Jan;21(1):153-163.e12
pubmed: 35842121
Gut. 2014 Aug;63(8):1258-64
pubmed: 24041539
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Inflamm Bowel Dis. 2011 Aug;17(8):1759-68
pubmed: 21744431
J Crohns Colitis. 2022 Sep 8;16(9):1436-1446
pubmed: 35390141
Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53
pubmed: 18550004
Adv Ther. 2022 Jun;39(6):2342-2364
pubmed: 34988877
Lancet. 1980 May 24;1(8178):1134-5
pubmed: 6103463
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
N Engl J Med. 2004 Feb 26;350(9):876-85
pubmed: 14985485
Inflamm Bowel Dis. 2017 Jul;23(7):1210-1217
pubmed: 28445244
Clin Drug Investig. 2022 Jun;42(6):477-489
pubmed: 35657560
Gastroenterology. 2021 Jun;160(7):2340-2353
pubmed: 33676969
Aliment Pharmacol Ther. 2022 Feb;55(4):508-509
pubmed: 35092046